Show notes
In this edition, disparities among women in the surgical workforce, GSK withdraws belantamab mafodotin from US market, risk for lymphoma low after postmastectomy reconstruction, and more.
Read the full coverage here:
More women surgeon scientists receive NIH funding than in 2010, yet gender gaps remain
GSK to withdraw multiple myeloma therapy from US market
Risk for lymphoma after postmastectomy breast implant reconstruction ‘still extremely low’
Differences observed in adverse events of antibody-drug conjugates
FDA approves Hemgenix as first gene therapy for treatment of hemophilia B
References:
Kinslow CJ, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.43396.
Saif A, et al. JAMA Surg. 2022;doi:10.1001/jamasurg.2022.5157
